ESSA Change To Inventory vs Depreciation Analysis
EPIX Stock | USD 1.60 0.01 0.62% |
ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Change To Inventory and its Depreciation accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.
Change To Inventory vs Depreciation
Change To Inventory vs Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Change To Inventory account and Depreciation. At this time, the significance of the direction appears to have almost no relationship.
The correlation between ESSA Pharma's Change To Inventory and Depreciation is 0.14. Overlapping area represents the amount of variation of Change To Inventory that can explain the historical movement of Depreciation in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Change To Inventory and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Inventory of ESSA Pharma are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Change To Inventory i.e., ESSA Pharma's Change To Inventory and Depreciation go up and down completely randomly.
Correlation Coefficient | 0.14 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Depreciation
Depreciation indicates how much of ESSA Pharma value has been used up. For tax purposes ESSA Pharma can deduct the cost of the tangible assets it purchases as business expenses. However, ESSA Pharma must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Selling General Administrative is likely to drop to about 8.2 M in 2024. Tax Provision is expected to grow at the current pace this year
ESSA Pharma fundamental ratios Correlations
Click cells to compare fundamentals
ESSA Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ESSA Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 80.6M | 198.2M | 169.5M | 149.1M | 128.1M | 69.8M | |
Other Current Liab | 24.2M | 39.2M | 36.4M | 1.4M | 773.5K | 734.8K | |
Total Current Liabilities | 1.2M | 3.9M | 2.3M | 3.5M | 3.3M | 3.0M | |
Total Stockholder Equity | 79.2M | 194.0M | 167.1M | 145.6M | 128.1M | 65.5M | |
Net Debt | (56.3M) | (137.5M) | (56.9M) | (33.6M) | (103.4M) | (98.2M) | |
Retained Earnings | (81.0M) | (117.8M) | (152.9M) | (179.5M) | (208.0M) | (197.6M) | |
Accounts Payable | 678.6K | 1.4M | 954.6K | 2.0M | 2.4M | 1.5M | |
Cash | 56.3M | 137.8M | 57.1M | 33.7M | 103.7M | 108.9M | |
Non Current Assets Total | 55.2K | 567.7K | 446.0K | 325.3K | 552.4K | 401.0K | |
Non Currrent Assets Other | (200.7K) | 277.6K | 259.5K | 257.2K | 257.0K | 190.5K | |
Cash And Short Term Investments | 56.3M | 194.9M | 57.1M | 148.1M | 126.8M | 133.1M | |
Other Current Assets | 1.7M | 2.2M | 1.8M | 585.4K | 673.2K | 1.2M | |
Other Stockholder Equity | 31.2M | 36.4M | 44.0M | 49.0M | 130.2M | 136.7M | |
Total Liab | 1.3M | 4.2M | 2.4M | 3.5M | 3.5M | 4.5M | |
Total Current Assets | 80.6M | 197.6M | 169.5M | 148.8M | 127.6M | 69.5M | |
Common Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 335.9M | |
Other Liab | 19.6K | 16.5K | 127.4K | 20.4K | 18.3K | 17.4K | |
Net Tangible Assets | 49.0M | 79.2M | 194.0M | 167.1M | 192.2M | 201.8M | |
Other Assets | (55.2K) | 198.2M | (446.0K) | 115.4M | 24.1M | 30.8M | |
Net Receivables | 309.5K | 489.0K | 6.2K | 135.1K | 163.0K | 154.8K | |
Liabilities And Stockholders Equity | 80.6M | 198.2M | 169.5M | 149.1M | 128.1M | 75.6M | |
Inventory | 420.5K | (360.8K) | (309.5K) | 110.6M | 127.2M | 133.6M | |
Short Term Debt | 59.1K | 120.7K | 133.8K | 80.3K | 124.1K | 117.9K | |
Common Stock Shares Outstanding | 22.4M | 38.5M | 44.0M | 44.1M | 44.3M | 46.5M | |
Non Current Liabilities Total | 127K | 230.6K | 77K | (71.0) | 205.2K | 194.9K | |
Short Long Term Debt Total | 59.1K | 331.0K | 209.8K | 80.3K | 329.3K | 312.8K | |
Net Invested Capital | 79.2M | 194.0M | 167.1M | 145.6M | 124.6M | 107.6M | |
Net Working Capital | 79.1M | 193.7M | 166.7M | 145.3M | 124.3M | 106.0M | |
Capital Stock | 131.1M | 277.4M | 278.1M | 278.2M | 279.9M | 213.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.